AZD-0022

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameAZD-0022
Drug Alias NameAZD0022AZD-0022
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcAstraZeneca global R & D (China) Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A